亚洲社会药学

最多下载

一年内发表文章 | 两年内 | 三年内 | 全部 | 最近1个月下载排行 | 最近1年下载排行

当前位置： 最近1个月下载排行

Please wait a minute...


选择: 下载引用 EndNote Reference Manager ProCite BibTeX RefWorks 显示/隐藏图片

Select

1. On Predicting the Price of Chinese Herbal Medicines Based on the Combination Model of ARIMA and GM (1, 1): A Case Study of Panax Notoginseng Wu Wanlin, Wang Shuling 亚洲社会药学

Select

2. Dynamic Evaluation on Scientific and Technological Innovation Efficiency of Medical Universities in China Tan Xiaodong, Chen Yuwen 亚洲社会药学

Select

3. Measures to Speed up Drug Review Process in Japan and Its Implications Shi Wenwen, Sun Lihua 亚洲社会药学

Select

4. Group Purchasing Organizations (GPOs) in the U.S.: Development and Reform Jin Jing, Xiong Jiamei, Yang Yue, Huang Zhe 亚洲社会药学    2019, 14 (3): 100-109.   摘要 （593）      PDF（pc） （2783KB）（4460）    可视化    收藏 Objective To study the characteristics, specific functions and policy improvement process of the Group Purchasing Organizations (GPOs) in the U.S. and to provide references for drug group purchasing practices in China. Methods Domestic and foreign relevant literatures, websites were reviewed or searched to analyze the functions and policy improvement process of the GPOs in the U.S. so as to provide references for drug group purchasing practices in China. Results and Conclusion As a third party in the U.S. GPOs has formed a relatively integrated business process and projects service system after long-term development. Supported by corresponding policies and industrial regulations, GPOs have made a great contribution to control the growth of medical and healthcare expenses and improve the efficiency of medical institutions, and its development experience can enlighten the practices in China. 相关文章 | 多维度评价

Select

5. Development of Licensed Pharmacists in China: Dilemma and Opportunity De Xianhui, An Lianyu, Wang Shuling 亚洲社会药学    2019, 14 (4): 192-203.   摘要 （395）      PDF（pc） （1418KB）（451）    可视化    收藏 Objective To study the current status of licensed pharmacists in China, and to make suggestions for the sound development of regulation authorities and licensed pharmacists. Methods Literature review and data research were conducted to analyze the status of examinations, registration, academic qualification and professional composition of licensed pharmacists. And SWOT method was used to analyze the strengths, weaknesses, opportunities and threats for the development of licensed pharmacists. Results and Conclusion Licensed pharmacists have such advantages and opportunities as professionalism, favorable policies, and continuous expansion of market demand. However, they also face disadvantages and threats, such as low service capacity, weak service awareness and low social status. According to the results of SWOT analysis, it is suggested that the government should make use of the advantages of artificial intelligence to build a regulatory information platform and a public platform for electronic prescriptions. Meanwhile, a national accreditation agency for continuing education should be established, and academic exchanges between regional licensed pharmacists and physicians must be organized regularly. Besides, licensed pharmacists can use mobile phones and other information devices to keep abreast of national policy and new medical information. Therefore, their services will be recognized by the public, thus to protect the drug safety for the public. 相关文章 | 多维度评价

Select

6. Present Situation and Enlightenment of Post-Approval Change Management of Drugs in China, USA and EU Lv Xiaowen, Huang Zhe 亚洲社会药学    2023, 18 (1): 17-23.   摘要 （306）      PDF（pc） （358KB）（241）    可视化    收藏 Objective To provide suggestions for further improvement of China’s drug post-approval change management system. Methods The current legal and regulatory requirements of post-approval change management systems of drugs in USA, EU and China were compared and analyzed. Results and Conclusion The post-approval change management of drugs is an important part of the whole life-cycle management of drugs. However, there are still some problems in China’s current post-approval change management systems. According to the model and requirements of the post-approval change management systems of the USA and EU, this paper proposes the following suggestions for the improvement of China’s post-approval change management system. Firstly, electronic files for licensed products should be created. Then, regulatory standards at the national level must be unified. Lastly, the concept of product life cycle management should be implemented. 相关文章 | 多维度评价

Select

7. Study on the Connotation and Application of Real World Evidence Ding Wei, Yang Yue 亚洲社会药学    2020, 15 (3): 121-125.   摘要 （517）      PDF（pc） （333KB）（647）    可视化    收藏 Objective To define the concepts and characteristics of real world data (RWD), real world research, real world evidence (RWE) and other related terms so as to better apply RWE to serve the whole life cycle monitoring of pharmaceutical products. Besides, some reference can be provided for drug supervision and medical services to further standardize the clinical application of drugs. Methods Through literature retrieval at home and abroad, the development process of exploring RWE in Europe and America was briefly introduced, and its development status in China was compared and analyzed as well. The application fields of RWE were explored based on the whole life cycle of drugs. Results and Conclusion RWE can provide proof for drug life cycle regulatory evaluation. Some European countries and the United States gradually apply RWE to regulatory decision-making and related policy research. Due to its bright prospect, China is also strengthening the expansion of RWE application fields and exploring its use in-depth. 相关文章 | 多维度评价

Select

8. The Development Opportunities and Dilemmas of Telemedicine – Base on the Perspective of Medical Resource Distribution Liu Liang, Wang Shuling, Zhi Yuanyuan, An Lianyu 亚洲社会药学    2022, 17 (1): 76-87.   摘要 （409）      PDF（pc） （1715KB）（377）    可视化    收藏 Objective To discuss issues related to telemedicine in the context of the “Internet plus” and the prevention of novel coronavirus in early 2020, so as to provide some reference for the rapid development of Internet plus telemedicine. Methods Literature analysis method was used to summarize the current status of telemedicine at home and abroad. Descriptive statistical analysis and comparative analysis were also conducted to analyze the data of population and health in the “China Health Statistical Yearbook” and “China Statistical Yearbook” from 2009 to 2018. Results and Conclusion The distribution of medical demand and medical resources is uneven in 31 provinces, municipalities and autonomous regions, such problems are more serious between urban and rural areas in different regions. The population’s demand for medical care and the allocation of medical resources have the characteristics of positive correlation, large urban-rural differences and regional imbalance. Confronted with the situation that the uneven distribution of medical resources provides potential development opportunities for telemedicine and the difficulties in the further development of telemedicine, the government should formulate policies to improve the publicity of telemedicine, setting up a full coverage of telemedicine service system. Besides, hospitals should ensure the information security monitoring. 相关文章 | 多维度评价

Select

9. Real-World Evidence Supporting New Drug Review and Approval in European Union and Its Enlightenment to China Lan Yipeng, Huang Zhe 亚洲社会药学    2021, 16 (3): 203-208.   摘要 （344）      PDF（pc） （793KB）（317）    可视化    收藏 Objective To analyze the application of real-world evidence (RWE) in the field of medicine in European Union, and provide suggestions for RWE supporting the review and approval of new drugs in China. Methods The European Medicines Agency (EMA) and other databases were used to search relevant documents for analyzing the European Union’s new drug review and approval process with the support of RWE. Results and Conclusion The European Union carrying out new drug review and approval with the support of RWE has just begun. The decision-making process includes three stages such as new drug research and development, review, and approval. However, there are some challenges in data quality, research methods, evidence sufficiency, and research process of RWE supporting the European Union in reviewing and approving new drugs. At present, RWE can accurately grasp the clinical effects of drugs and improve the safety and effectiveness in the process of assisting the review and approval of new drugs. At the same time, RWE also can promote the development and application of Traditional Chinese Medicine (TCM) and help find out the potential value of TCM such as new indications. 相关文章 | 多维度评价

Select

10. Project Management of Generic Drug R&D and Registration in the United States Mao Xiaofang, Qi Xiang, Zhou Fengxiang 亚洲社会药学

Select

11. Research on the Construction of Evaluation Model for the Development of Biopharmaceutical Park in China Zhang Zongjie, Wu Zhiang 亚洲社会药学    2023, 18 (4): 387-397.   摘要 （36）      PDF（pc） （464KB）（88）    可视化    收藏 Objective To study the influencing factors on the development of biopharmaceutical park, and to construct an evaluation model of the influencing factors for biopharmaceutical park in China. Methods By analyzing various factors affecting biopharmaceutical parks, an evaluation index system of biopharmaceutical parks and an evaluation model of influencing factors of biopharmaceutical park development based on fuzzy group decision making were established. Results and Conclusion Factors such as research and development (R&D) funding investment, incentive for transformation of scientific and technological achievements, and industrial clusters have a greater impact on the development of biopharmaceutical industrial parks in China. Local governments should increase the investment in R&D funding. Besides, they should pay attention to the incentive of transformation of scientific and technological achievements to improve the innovation ability of enterprises. Meanwhile, they should promote the clustering of high-tech enterprises to comprehensively enhance the healthy development of biopharmaceutical parks in China. 相关文章 | 多维度评价

Select

12. CRO in China: SWOT Analysis and Development Strategies Ding Ling, Dong Li 亚洲社会药学

Select

13. A Comparison Study Between EQ-5D-3L and the New Version EQ-5D-5L 亚洲社会药学    2016, 11 (1): 25-30.   摘要 （309）      PDF（pc） （537KB）（458）    可视化    收藏 Objective To make a comparison study between EQ-5D-5L and EQ-5D-3L in order to promote the application of EQ-5D-5L. Methods A survey of 240 respondents was done and the performance of EQ-5D-3L and EQ-5D-5L was assessed according to the inconsistency and redistribution properties at all levels. The discriminatory power and sensitivity of EQ-5D-3L and EQ-5D-5L were explored according to Shannon index (H’), Shannon evenness index (J’) and ceiling effect. And the reliability and validity of EQ-5D- 3L and EQ-5D-5L were analyzed according to Cronbach’α and criterion validity. Results and Conclusion The average inconsistent rate and size of EQ-5D-3L and EQ-5D-5L were 2.33% and 1.04, respectively. Compared with EQ-5D-3L, the state of health of EQ- 5D-5L dropped from 74.17% to 65.42%, and the ceiling effect decreased as well. The Shannon indexes of all dimensions of EQ- 5D-5L were better than EQ-5D-3L. Except for pain/discomfort, the Shannon evenness indexes of EQ-5D-5L were also better than EQ-5D-3L. The Cronbach’α of EQ-5D-5L increased from 0.514 to 0.707. Except for self-care, the Spearman’s rank correlation coefficient between EQ-5D-5L and EQ-VAS also increased. Therefore, EQ-5D-5L gains more advantages than EQ-5D-3L and should be promoted. 相关文章 | 多维度评价

Select

14. 醫藥物流中心配送優化模型設計 傅書勇;孫淑軍 null    2007, 2 (3): 90-92.   摘要 （2651）      可视化    收藏 目的 設計醫藥物流中心配送優化模型。方法 運用線性規劃理論進行分析。結論與結果 建立滿足未來需求的物流中心配送優化模型及其最優配送量不變的可變因素變化範圍。 相关文章 | 多维度评价

Select

15. Regulation of Drug Clinical Trials in China: Course and Development Trend Zhang Xu, Tian Lijuan 亚洲社会药学    2019, 14 (3): 87-91.   摘要 （323）      PDF（pc） （2691KB）（483）    可视化    收藏 Objective To provide a basis for future regulation reform of drug clinical trials in China in the context of the continuous deepening of drug regulation reform. Methods Literature review and regulation study were conducted to analyze the course and development trend of drug clinical trial regulation in China. Results and Conclusion It is found that the regulation system and the standardization for clinical trials in China are gradually improving, but there is still a gap compared with developed countries. In the future, the regulation authorities still need to further improve relevant regulations, clarify regulation responsibilities, and to improve the drug clinical trial review system to ensure the quality of clinical trials and the safety and effectiveness of listed drugs. 相关文章 | 多维度评价

Select

16. Research on Reimbursement Management of Innovative Drugs Abroad and Its Enlightenment to China Yu Hanshuang, Huang Xianqin, Wang Huiyan, Sun Lihua 亚洲社会药学    2024, 19 (1): 1-8.   摘要 （53）      PDF（pc） （486KB）（46）    可视化    收藏 Objective To analyze the reimbursement policies of innovative drugs in some developed countries, and to provide reference for future reimbursement management in China. Methods Literature research method was used to study the policies related to the reimbursement management of innovative drugs in Germany, France and Japan, and their successful experience was summarized. Results and Conclusion China should establish an open and transparent value evaluation standard to improve the medical insurance reimbursement management of innovative drugs. Besides, the value of innovative drugs should be taken as an important basis for reimbursement decisions, and an independent third-party value evaluation agency must be established. 相关文章 | 多维度评价

Select

17. Current Situation and Suggestions on the Development of Diagnosis Related Group (DRG) Policy in China Dong Yujiao, Wang Shuling 亚洲社会药学    2022, 17 (4): 367-375.   摘要 （351）      PDF（pc） （571KB）（210）    可视化    收藏 Objective To implement the national diagnosis related group (DRG) policy smoothly, and gradually move towards value medicine and fine management, some suggestions are put forward for improving medical service efficiency, saving medical insurance fund, and reducing the burden of patients, so as to realize the win-win situation of medical insurance and patients. Methods Based on the experience of the United States, Australia, and Germany, the policy implementation background and development process in China were summarized. The advantages and disadvantages of single disease payment method, disease score payment method, and diagnosis related groups - prospective payment system (DRG-PPS) method were compared, and then the problems were found out. Results and Conclusion In view of the imperfect information system, lack of professional talents, and uneven progress of each pilot, it is proposed that relevant departments should pay more attention to the construction and improvement of coding and other information systems, cultivate professional talents, promote the reform of DRG payment technology specification and grouping technology combined with national pilot project, thus enhancing the application and in-depth development of DRG policy in China. 相关文章 | 多维度评价

Select

18. An Analysis of Marketing Trend of IVD in China Gu Chi, Chen Yuwen 亚洲社会药学    2020, 15 (2): 83-88.   摘要 （527）      PDF（pc） （908KB）（729）    可视化    收藏 Objective To contribute to the in vitro diagnosis (IVD) industry taking a leading position and developing sustainably in the market, and to help enterprises to adopt a variety of methods to strengthen its capacity. Methods Current status of IVD industry was analyzed and some strategies for the development of IVD industry were put forward in combination with the characteristics of the industry. Then the exterior environment of IVD industry and the development of marketing were analyzed so as to help increase the market shares of Chinese IVD industry in the global market. Results and Conclusion Chinese IVD industry was analyzed comprehensively from various perspectives on the basis of study of the history of Chinese IVD industry and foreign IVD industries. Therefore, some strategies are put forward. 相关文章 | 多维度评价

Select

19. Design of Pharmaceutical Care Process for Retail Pharmacies Based on Pareto Analysis An Lianyu, Liu Linchuan, Wang Shuling 亚洲社会药学    2022, 17 (1): 50-60.   摘要 （361）      PDF（pc） （1555KB）（479）    可视化    收藏 Objective To study the problems of pharmaceutical care in retail pharmacies and provide reference for the standardized development of pharmaceutical care in China. Methods Based on the literature of CNKI database, Pareto analysis was used to study the present situation of pharmaceutical care in retail pharmacies. Then the following problems in pharmaceutical care were found such as low personnel professional quality, inadequate attention, imperfect laws and regulations, and lack of standard service process. As to the first three problems, there were more research references. But there was less literature on the standard care process. Results and Conclusion Focusing on the customer demand, taking drug sales process as the basic framework of pharmaceutical care standardized process, and combining with the collaboration, the service process including prescription drugs review and OTC drugs purchase consultation is established. This process elaborates the division of staff services as well as the service standards in pre-sale, on-sale, and after-sale stages. Besides, it also puts forward some advice for the previous three problems, which will ensure the smooth implementation of pharmaceutical care in drugstores. 相关文章 | 多维度评价

Select

20. The Expanding Roles of Hospital Pharmacists in Clinical Drug Trials in China Zhao Shanshan, Zhang Boquan, Wang Hongyun 亚洲社会药学    2022, 17 (3): 229-235.   摘要 （266）      PDF（pc） （789KB）（140）    可视化    收藏 Objective To aim at summarizing the role of hospital pharmacists in clinical drug trials in China against the background that hospital pharmacists have already involved in team-based patient care. Methods The roles and responsibilities of Chinese hospital pharmacists were listed and categorized. Results and Conclusion There has been an upsurge in clinical drug trials in China. Hospital pharmacists play increasingly important roles in all aspects of clinical trials, such as stakeholder liaisons, protocol developers, ethics committee members, research team members, study drug managers, and subject intervention agents. Hospital pharmacists are an integral part of a clinical drug trial multidisciplinary team. Their value is reflected in several pharmacist-led or pharmacist-participating clinical trials as well as the trial project management position within hospitals. Pharmacists should be the designers, researchers, managers and supervisors of clinical drug trials. We expect that all clinical trial projects will include hospital pharmacists in their research teams soon. 相关文章 | 多维度评价

Select

21. Introduction of Drug Re-evaluation in Foreign Countries and Its Enlightenment to China Liu yue, Sun Lihua 亚洲社会药学

Select

22. Analysis of the Current Situation of Active Pharmaceutical Ingredient (API) Export in China Kong Deqiang, Dong Li 亚洲社会药学    2019, 14 (3): 126-134.   摘要 （483）      PDF（pc） （3643KB）（611）    可视化    收藏 Objective To analyze the problems of API export in China and to study the current international and domestic trading environment. Methods Data statistical analysis was used to study the export situation of APIs, and PEST was applied to analyze the current export problems. Results and Conclusion API export in China is now experiencing a growth period and the international trading environment is constantly improving. 相关文章 | 多维度评价

Select

23. Management of Orphan Drug Reimbursement Abroad and Its Enlightenment to China Ma Jia, Li Xiaoqi, Raela·Abduhilil, Sun Lihua 亚洲社会药学    2021, 16 (4): 352-357.   摘要 （335）      PDF（pc） （819KB）（318）    可视化    收藏 Objective To analyze relevant policies and measures on the management of orphan drug reimbursement in foreign countries to provide a reference for future reimbursement management in China. Methods According to the percentage of health care expenditure in GDP, the completeness of rare disease policies, and the total population, Russia, Australia, and India were selected as the reference. Based on the existing literature, the main content and characteristics of the reimbursement of rare disease drugs were analyzed. Results and Conclusion Russia manages rare diseases in the form of lists. Special rare diseases are reimbursed by federal or regional finances, and ordinary rare diseases are reimbursed by statutory medical insurance funds. Orphan drugs in Australia are included in the pharmaceutical benefits scheme (PBS) and the lifesaving drugs program (LSDP), LSDP provides fully reimbursed drugs for eligible rare disease patients. India’s proposal takes health system sustainability into consideration. China should carry out epidemiological research to legally determine the rare diseases, establish reasonable reimbursement standards, and improve the multi-level reimbursement system. 相关文章 | 多维度评价

Select

24. Cause Analysis and Preventive Measures of Drug Shortage Zhou Ziyang, Ma Jia, Liu Fuyao, Liu Yuhan, Sun Lihua 亚洲社会药学    2022, 17 (2): 120-131.   摘要 （319）      PDF（pc） （1810KB）（321）    可视化    收藏 Objective To study the current situation and the root cause of drug shortage in China, and put forward countermeasures and suggestions accordingly for relevant national policy decisions. Methods Based on literature research, questionnaire survey and expert consultation, the causes of drug shortage in China were comprehensively investigated, and fishbone diagram was used to further analyze the logical relationship among the causes. Results and Conclusion The main reasons for the shortage of drugs are the low profit of production enterprises and insufficient active pharmaceutical ingredients (APIs). The other reasons include uncertain demand, standard problem and few exclusive manufacturers. Besides, the monopoly of circulation enterprises also leads to the shortage of drugs to a certain extent. It is suggested that we should increase the punishment of monopoly, optimize the market environment, and establish a reasonable drug price mechanism. In addition, enterprises should participate in the information communication platform of medical institutions to solve the asymmetry between supply and demand. The research on clinical drugs to substitute drugs in need should be strengthened, and the reporting system of drug discontinuation should be improved. 相关文章 | 多维度评价

Select

25. Analysis of Factors Affecting Online Drug Purchase – Based on Factor Analysis Wang Shuling, Liu Liang, Zhi Yuanyuan 亚洲社会药学    2022, 17 (3): 268-280.   摘要 （236）      PDF（pc） （2843KB）（162）    可视化    收藏 Objective To explore the factors affecting consumers’ online drug purchases, and construct models of these factors to provide references for the development and popularization of online pharmacies. Methods Through searching, classifying, integrating, and extracting evaluation indexes of online pharmacies in literature, the indexes of factors affecting online drug purchases were initially established. Then SPSS24.0 was used for data analysis, and finally factor analysis was applied for screening and combining the indexes. Results and Conclusion A model of influencing factors for online drug purchases is set up with 4 factors and 14 indexes. Convenient service is the most important factor affecting online drug purchases. Highly educated young people prefer to buy drugs online. At present, online drug purchase is only a supplement to the purchase of drugs in offline pharmacies, and the penetration rate is not high. Online pharmacies should give full play to their advantages in terms of drug types, prices, logistics and after-sales services to make online drug purchases more mainstream. 相关文章 | 多维度评价

Select

26. Investigation on the Current Situation of China’s DTP Pharmacy and Suggestions for Its Development Wen Dong, Dou Lele, Sun Yuyuan, Wang Shuling 亚洲社会药学    2023, 18 (2): 165-176.   摘要 （351）      PDF（pc） （1965KB）（395）    可视化    收藏 Objective To summarize the main characteristics and development approaches of direct-to-patient (DTP) pharmacies, and to explore its future development trend. Methods Firstly, relevant policies of DTP pharmacies were sorted out based on some documents on the government website, and related articles were studied. Secondly, 499 DTP pharmacies were investigated. Finally, the current status of the industry was summarized and analyzed. Results and Conclusion Policies on China’s DTP pharmacy have been constantly improved. According to industry standards, the current compliance rate of DTP pharmacies is about 46.09%. In terms of varieties, the market share concentration rate of biological products is higher than that of chemical drugs. The regional distribution of these drugs is mainly concentrated in the central and eastern provinces. However, 63.45% of DTP pharmacies have less than 50 product specifications. DTP pharmacies have an average of 7.3 pharmacy technicians and 2.3 licensed pharmacists, which is higher than that of ordinary pharmacies. Due to the policy promotion, DTP pharmacies will be paid more attention by the public and the government, and the market share will become larger than before. Patients shifting from hospitals to drug-to-pharmacies can make them better layout. Besides, pharmaceutical services will become more specialized, and disease division will be more detailed. With the deepening of medical reform and the continuous improvement of national medical security as well as drug procurement and medical insurance payment methods, DTP pharmacies can play an important role in the national basic medical security system. 相关文章 | 多维度评价

Select

27. Social Responsibility of the Pharmaceutical Manufacturers in China: Current Status and Countermeasures Li Chunyu, Zhao Yinghuan 亚洲社会药学

Select

28. The Analysis of Marketing Strategy of Plendil Fu Geyang, Tian Lijuan 亚洲社会药学    2020, 15 (1): 37-43.   摘要 （537）      PDF（pc） （749KB）（762）    可视化    收藏 Objective To provide marketing strategies suitable for the characteristics of the Chinese market by determining the strengths, weaknesses, opportunities and challenges of Plendil through SWOT analysis. Methods SWOT analysis of Plendil shows that the product is well-known with safety, tolerance, excellent performance, and good brand image. In addition, great market potential, and the gradual improvement of the medical market and the health insurance system all provide an exciting opportunity for its development. However, weaknesses and threats still exist, including unsound marketing policy and remuneration incentive system, poor channel control, fierce market competition, competition from foreign companies and domestic generic drugs, and the intensified state supervision efforts. Accordingly, our company shall speed up the design of marketing portfolio strategy through 4P theory. Results and Conclusion Establish brand image and ensure high quality products are conducive to maintaining advantages; Improve sales cost policy and salary incentive system, and strengthen channel control are conducive to overcoming disadvantages; Actively carrying out academic promotion is conducive to seizing opportunities; Accelerating product upgrading, formulating reasonable pricing strategies and developing relationship marketing are conducive to the company to cope with threats and maintain an advantageous position in the fierce market competition. 相关文章 | 多维度评价

Select

29. Reducing the Internal Difference Error Rate in Hospital Pharmacies: From the Angle of Quality Control Circle Wang Shuling, Lei Yingzi, Liu Linchuan, Wang Ruili, He Yalan 亚洲社会药学    2020, 15 (2): 73-82.   摘要 （425）      PDF（pc） （1040KB）（512）    可视化    收藏 Objective To improve the management level of pharmacy dispensing center, reduce dispensing errors and promote the safety of drug use. Methods Hospital pharmacies could be managed according to the theory of quality control circle (QCC). Based on the ten steps of QCC, the internal difference error rate in pharmacies could be reduced. Results and Conclusion The error rate of pharmacies was reduced from 2.74‰ to 0.57‰, and the goal achievement rate was 108.466. Besides, the progress rate reached 84.82%. The abilities of circle members were improved, and the operation of pharmacy was more standardized. The activity of QCC is helpful to reduce the internal difference error rate, improve the operation level of pharmacy and ensure the safety of drug use. 相关文章 | 多维度评价

Select

30. Research on Prediction of the Scale of OTC Drug Market in China Based on Quantitative Analysis Xu Yang, Xu Lang, Xue Aoming 亚洲社会药学    2020, 15 (3): 145-152.   摘要 （297）      PDF（pc） （604KB）（442）    可视化    收藏 Objective To analyze the scale of domestic OTC drug market and its influencing factors, so as to predict its future market and provide a scientific basis for pharmaceutical enterprises to grasp the opportunities in the market. Methods The scale of OTC drug market from 1999 to 2018 in China and its influencing factors were analyzed by unit root test, Granger causality test and co-integration test. Results and Conclusion From the perspective of the global pharmaceutical market, OTC drug market has broad prospects and great development potential. Since the influence of GDP and the number of elderly populations on the scale of OTC drug market is positive, the predicted growth rate of OTC market in the next three years is 5.82%, 5.86% and 5.90%, respectively. 相关文章 | 多维度评价

Select

31. Research on the Status Quo and Countermeasures of Patent Application in Liaoning Biopharmaceutical Industry Based on Patent Map Ma Junhong, Zhang Wenfeng, Liu Yue, Yuan Hongmei, Zhang Dawei 亚洲社会药学    2021, 16 (2): 145-153.   摘要 （288）      PDF（pc） （1053KB）（367）    可视化    收藏 Objective To study the patent map and the relevant theories of the patent development of biopharmaceutical industry for conducting a comprehensive and in-depth analysis of the problems in patent application in Liaoning biopharmaceutical industry. Methods Literature review, information visualization method, empirical analysis method and comparative analysis method were used to research the problems in the patent application. Results and Conclusion While developing biopharmaceutical industry, Liaoning provincial government should strengthen the protection of pharmaceutical patents, creating a new R&D mode of “university + research institutes + enterprises + individuals” to broaden the scope of technical fields. Then, its biopharmaceutical industry will be developed in an all-round way. Besides, it should closely follow the national development direction so that the biopharmaceutical industry in Liaoning Province will have a bright future. 相关文章 | 多维度评价

Select

32. A Case Analysis of the Influencing Factors of Job Satisfaction of Licensed Pharmacists in Retail Pharmacies Based on SEM - Taking R Retail Pharmacy for an Example Chen Jing, Cui Yuxue, Chen Jing 亚洲社会药学    2022, 17 (4): 317-332.   摘要 （210）      PDF（pc） （1122KB）（202）    可视化    收藏 Objective To explore the influencing factors on job satisfaction of licensed pharmacists in R retail pharmacy, and to provide a reference for improving the job satisfaction of licensed pharmacists in China. Methods Through literature research and satisfaction questionnaire, 349 licensed pharmacists in R retail pharmacy were investigated. Then, the influencing factor equation model was constructed by factor analysis and structural equation method. Results and Conclusion The overall adaptation of the structural equation model was well established. The job satisfaction of licensed pharmacists in R retail pharmacy was closely related to interpersonal relationship, work characteristics, good management, salary and growth opportunity, and it was not significantly correlated with job environment. Therefore, work characteristics influenced most, followed by salary. Five key factors affecting the job satisfaction of licensed pharmacists in R retail pharmacy are summarized in this paper. It is suggested to adjust corresponding key factors such as work characteristics and salary, so as to improve job satisfaction of licensed pharmacists in the same industry. 相关文章 | 多维度评价

Select

33. The Impact of Population Aging on the Expenditure of Medical Insurance Fund for Urban Workers in China Wang Shuling, Dou Lele, Shi Hui, Huang Zhe 亚洲社会药学    2023, 18 (3): 239-246.   摘要 （60）      PDF（pc） （2653KB）（59）    可视化    收藏 Objective To explore the impact of population aging on the expenditures of medical insurance funds against the background that great changes in population structure influences economic development. Methods Through analyzing the impact of the population aging, the income and accumulated balance of the medical insurance fund, and other related factors on the expenditure of the medical insurance fund, development status of the medical insurance fund for urban employees in China since 2003 was obtained. Stata 16.0 was used to perform multiple linear regression analysis on related factors to determine the correlation between population aging and the change in medical insurance expenditures. Results and Conclusion The factors that have a greater impact on the expenditure of the medical insurance fund are the amount of income from the medical insurance, followed by the number of people over the age of 65 in China and the urban retired employees participating in medical insurance. We should focus on the sustainable development of the urban employee medical insurance fund to deal with the threat of aging. 相关文章 | 多维度评价

Select

34. Research on Setting up Patent Risk Management System in Medical colleges and universities in China Jin Quanyuan, Lin Xiaohui, Dong Li 亚洲社会药学

Select

35. Beijing Medical Reform of Separating Dispensing from Prescription: Its Impact on Community Hospitals —Taking the Community Health Service Center of Beijing Language and Culture University as an Example Zhao Shiqing, Guo Qing, Zhang Fang 亚洲社会药学

Select

36. Bibliometric Analysis of Drug Supply Chain in China Cao Linlin, Wu Zhi’ang 亚洲社会药学    2020, 15 (3): 159-170.   摘要 （349）      PDF（pc） （1288KB）（878）    可视化    收藏 Objective To study the development trend and hotspot of China’s drug supply chain in terms of bibliometrics to provide some reference for transforming and upgrading China’s pharmaceutical circulation industry. Methods Based on the data related to drug supply chain research from 1999 to 2019 collected by CNKI, Wanfang and VIP, software such as bibliographic information co-occurrence mining system (BICOMS) version 2.0, University of California Irvine Network (UCINET) version 6.0, and graphical clustering toolkit were used to measure and conduct visual analysis of the domestic drug supply chain research literature. Results and Conclusion Through literature analysis, it can be seen that the current research on drug supply chain in China mainly focuses on drug procurement and cost control, zero inventory control of hospital pharmacy, optimization and risk management of drug supply chain, and information of supply chain and logistics of pharmaceutical enterprises. Combining with the “Internet +” and other models, drug supply chain enterprise should optimize its management process according to the relevant national policy, promote information construction in all links of the supply chain, improve its transparency and ensure the quality and safety of drugs. The improvement of supply chain efficiency will enhance the transformation and upgrading of China’s pharmaceutical circulation industry. 相关文章 | 多维度评价

Select

37. Analysis of Drug Purchase and Pricing Decision under the Mode of Procurement with Target Quantity Qiao Zelin, Huang Zhe 亚洲社会药学    2021, 16 (1): 1-10.   摘要 （447）      PDF（pc） （1600KB）（527）    可视化    收藏 Objective To study the reasonable pricing strategy to effectively reduce the risk of drug supply disruption. This paper studies the vertical competition between drug purchasers and pharmaceutical enterprises, and the horizontal competition between different pharmaceutical enterprises. Based on the wholesale price of drugs made by pharmaceutical enterprises, drug purchasers adopt different procurement strategies. Methods A multi-stage game model was used to analyze the collusion and competition between two drug procurement parties. Results and Conclusion (1) Enterprise B can choose the optimal game strategies according to the stability of enterprise A; (2) Two procurement parties should choose collusion when the risk of supply interruption is low; (3) Emergency dual sourcing strategy is better than single sourcing strategy; (4) The optimal procurement quantity is irrelevant to the monotonicity of the stability of enterprise A in Cournot game. Through numerical analysis, the optimal decisions of pharmaceutical enterprises and drug purchasers are obtained respectively. 相关文章 | 多维度评价

Select

38. Policy Comparison between Shenzhen GPO and Guangdong Medicine Exchange Center Xiang You, Tian Lijuan 亚洲社会药学    2021, 16 (4): 290-294.   摘要 （358）      PDF（pc） （785KB）（360）    可视化    收藏 Objective To put forward some suggestions for improving the procurement policy of Shenzhen Pharmaceutical Group. Methods The literature research and comparative research were used to compare the policies between Guangdong’s centralized drug procurement and Shenzhen Pharmaceutical Group’s procurement so as to analyze their advantages and disadvantages. Results and Conclusion The purchasing model of Shenzhen group purchasing organization (GPO) can ensure the timely supply of medicines. Besides, the cross-regional alliance system helps to achieve a true price-for-quantity exchange, and a market-based price linkage mechanism can effectively reduce drug prices. However, the online drug catalogue of Shenzhen GPO cannot fully cover the actual needs of hospitals for procurement. The market-based price linkage may lead to problems of drug quality or shortage of drugs. Therefore, the number of batches of drugs should be increased online appropriately. Meanwhile, a mechanism must be established to guarantee the supply and quality of low-priced drugs. 相关文章 | 多维度评价

Select

39. Research on Patent Situation of Medical Devices in China Wu Chenxia, Yuan Hongmei 亚洲社会药学    2023, 18 (1): 30-39.   摘要 （142）      PDF（pc） （899KB）（128）    可视化    收藏 Objective To study the patent situation of medical device industry in China based on patent data. Methods The analysis function of the patent search software incoPat was used to analyze the patent situation from two perspectives: The overall situation and the technical level. Results and Conclusion At present, China’s medical device industry is developing rapidly under the leadership of enterprises as the main body of innovation, but only 16% of patents are authorized. In addition, the technology distribution of medical device industry is mainly related to diagnostic, surgical and identification medical devices and implantable devices, accounting for 59% of the main technology distribution, and their technical effects are mainly related to improving convenience, reducing complexity, and improving safety. The quality of patents related to medical device industry in China is low, the technology distribution is not rich enough, and the level of technical efficacy is low. 相关文章 | 多维度评价

Select

40. Research on the Countermeasures for the Development of Biopharmaceutical Industrial Parks in China Zhang Zongjie, Wu Zhiang 亚洲社会药学    2023, 18 (3): 232-238.   摘要 （51）      PDF（pc） （352KB）（145）    可视化    收藏 Objective To systematically analyze the current development status of biopharmaceutical industrial park in China, sort out the problems and put forward some countermeasures and suggestions. Methods Relevant literature was searched and reviewed to find out the problems faced by the development of biopharmaceutical industrial parks in China. Results and Conclusion Biopharmaceutical industrial parks are developing rapidly due to their unique industrial clustering advantages, but there are problems such as lack of overall planning at the top level, insufficient government support, imperfect talent support services and weak innovation capacity of the parks. It is recommended to promote the rapid development of biopharmaceutical industrial parks and biopharmaceutical enterprises by strengthening top-level design, increasing government support, focusing on talent introduction, and enhancing the innovative strength of the parks. 相关文章 | 多维度评价